Creating Oligonucleotide-Based Therapies. Delivering Answers.
Pioneering a new class of oligonucleotide-based therapies, Antibody Oligonucleotide Conjugates (AOCs™)
About Avidity
Avidity Biosciences is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. We utilize our proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases.
Approach
Avidity is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases.
In preclinical studies, using our proprietary AOC platform, we have demonstrated pharmacologic responses as measured by mRNA reduction in cell types and tissues including:
Programs
Avidity is initially focused on muscle tissue to demonstrate the capabilities of our AOCs and our muscle disease franchise consists of five programs.
Careers
Avidity – a great company for scientific superstars
Art Levin, Ph.D., Chief Scientific Officer“Scientific excellence leads to the healthcare breakthroughs of tomorrow. At Avidity, we draw upon the passions and the talents of experts across a range of scientific disciplines to deliver differentiated therapeutics for patients in need.”